{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:08:26Z","timestamp":1791590906084,"version":"4.3.4"},"reference-count":59,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2013,10,25]],"date-time":"2013-10-25T00:00:00Z","timestamp":1382659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:p>Objective: To evaluate the strength of evidence supporting a possible association between salmon calcitonin (SCT) use and cancer incidence. Data Sources: Searches of MEDLINE\/PubMed, MEDLINE\/OVID, and EMBASE (January 1973 to September 2013) were performed using the key search terms salmon calcitonin, humans, nasal calcitonin, and (for EMBASE only) randomized controlled trial. We also performed a manual review of data reviewed by the US Food and Drug Administration (FDA) committee in 2013. Study Selection and Data Extraction: All articles identified from the data sources were evaluated and all information deemed relevant was included for this review. Data Synthesis: Intranasal and injectable SCT are FDA-approved for the treatment of postmenopausal osteoporosis. After a safety signal suggested a possible link between SCT use and prostate cancer, the European Medicines Agency and FDA regulatory agencies conducted analyses of SCT randomized controlled trial data to assess cancer-related adverse events and to readdress the approval status of SCT. Eighteen studies were found that compared nasal or oral SCT and placebo. In 15 of the 18 studies, the percentage of malignancy was greater in the SCT arm. The studies varied in quality, outcomes, and length. Most of the studies had poor-quality methods to assess new cancer cases. Conclusions: Current evidence may suggest an association between SCT use and cancer incidence based on studies with poor-quality cancer assessment methods. However, considering the lack of demonstrated efficacy of SCT to reduce fractures, clinicians should consider discontinuing its use for osteoporosis treatment regardless of the FDA\u2019s final approval decision.<\/jats:p>","DOI":"10.1177\/1060028013509233","type":"journal-article","created":{"date-parts":[[2014,1,6]],"date-time":"2014-01-06T14:16:10Z","timestamp":1389017770000},"page":"1675-1684","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":86,"title":["Salmon Calcitonin Use and Associated Cancer Risk"],"prefix":"10.1177","volume":"47","author":[{"given":"Robert A.","family":"Overman","sequence":"first","affiliation":[{"name":"Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrudula","family":"Borse","sequence":"additional","affiliation":[{"name":"Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret L.","family":"Gourlay","sequence":"additional","affiliation":[{"name":"School of Medicine, University of North Carolina, Chapel Hill, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2013,10,25]]},"reference":[{"key":"bibr1-1060028013509233","doi-asserted-by":"publisher","DOI":"10.1210\/endo-70-5-638"},{"key":"bibr2-1060028013509233","first-page":"268","volume":"17","author":"Copp DH","year":"1994","journal-title":"Clin Invest Med"},{"key":"bibr3-1060028013509233","doi-asserted-by":"publisher","DOI":"10.1007\/BF00301940"},{"key":"bibr4-1060028013509233","unstructured":"US Food and Drug Administration. Drugs@FDA: FDA approved drug products, label and approval history, Miacalcin (nasal). http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=020313&DrugName=MIACALCIN&ActiveIngred=CALCITONIN%20SALMON&SponsorApplicant=NOVARTIS&ProductMktStatus=1&goto=Search.DrugDetails. Accessed September 21, 2013."},{"key":"bibr5-1060028013509233","unstructured":"US Food and Drug Administration. Drugs@FDA: FDA approved drug products, label and approval history, Miacalcin (injectable). http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=017808&DrugName=MIACALCIN&ActiveIngred=CALCITONIN%20SALMON&SponsorApplicant=NOVARTIS&ProductMktStatus=3&goto=Search.DrugDetails. Accessed September 21, 2013."},{"key":"bibr6-1060028013509233","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2010.526104"},{"key":"bibr7-1060028013509233","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-007-0490-1"},{"key":"bibr8-1060028013509233","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(00)00490-3"},{"key":"bibr9-1060028013509233","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.299.6697.477"},{"key":"bibr10-1060028013509233","doi-asserted-by":"publisher","DOI":"10.1007\/BF00297179"},{"key":"bibr11-1060028013509233","doi-asserted-by":"publisher","DOI":"10.1007\/s002239900076"},{"key":"bibr12-1060028013509233","first-page":"142","volume":"10","author":"Watts NB","year":"2004","journal-title":"J Manag Care Pharm"},{"key":"bibr13-1060028013509233","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200017040-00007"},{"key":"bibr14-1060028013509233","unstructured":"Crandall CJ, Newberry SJ, Diamant A, Treatment to prevent fractures in men and women with low bone density or osteoporosis: update of a 2007 report: Comparative Effectiveness Review No. 53. http:\/\/www.effectivehealthcare.ahrq.gov\/ehc\/products\/160\/1007\/CER53_LowBoneDensity_FinalReport_20120823.pdf. Accessed September 21, 2013."},{"key":"bibr15-1060028013509233","unstructured":"US Food and Drug Administration. Drugs@FDA: FDA approved drug products, label and approval history, Fortical. http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=021406&DrugName=FORTICAL&ActiveIngred=CALCITONIN%20SALMON%20RECOMBINANT&SponsorApplicant=UPSHER%20SMITH&ProductMktStatus=1&goto=Search.Label_ApprovalHistory. Accessed September 21, 2013."},{"key":"bibr16-1060028013509233","unstructured":"Miacalcin Team. Drug Regulatory Affairs, Miacalcin\u00ae (calcitonin-salmon), FDA Joint Reproductive Health Drugs and Drug Safety and Risk Management advisory committee meeting on the benefit\/risk of salmon calcitonin for the treatment of postmenopausal osteoporosis (Novartis Briefing Book). http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/ReproductiveHealthDrugsAdvisoryCommittee\/UCM341781.pdf. Accessed September 21, 2013."},{"key":"bibr17-1060028013509233","unstructured":"United States Department of Health and Human Services, Food and Drug Administration. Background document for meeting of Advisory Committee for Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committee. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/ReproductiveHealthDrugsAdvisoryCommittee\/UCM341779.pdf. Accessed September 21, 2013."},{"key":"bibr18-1060028013509233","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010372625"},{"key":"bibr19-1060028013509233","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2005.04.032"},{"key":"bibr20-1060028013509233","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1602"},{"key":"bibr21-1060028013509233","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2009.08.004"},{"key":"bibr22-1060028013509233","doi-asserted-by":"publisher","DOI":"10.1002\/art.22075"},{"key":"bibr23-1060028013509233","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2011.01.008"},{"key":"bibr24-1060028013509233","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.040715"},{"key":"bibr25-1060028013509233","unstructured":"US Department of Health and Human Services. Postmarketing surveillance programs. http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/ucm090385.htm. Accessed September 21, 2013."},{"key":"bibr26-1060028013509233","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(00)00539-8"},{"key":"bibr27-1060028013509233","doi-asserted-by":"publisher","DOI":"10.1038\/bonekey.2012.260"},{"key":"bibr28-1060028013509233","unstructured":"ClinicalTrials gov. Nordic Bioscience A\/S, Novartis. Efficacy and safety of oral salmon calcitonin in patients with knee osteoarthritis. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00486434. Accessed September 21, 2013."},{"key":"bibr29-1060028013509233","unstructured":"ClinicalTrials gov. Nordic Bioscience A\/S, Novartis. Efficacy and safety of oral salmon calcitonin in patients with knee osteoarthritis (OA 2 study). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00704847. Accessed September 21, 2013."},{"key":"bibr30-1060028013509233","unstructured":"ClinicalTrials gov. Nordic Bioscience A\/S, Novartis. A study to evaluate oral salmon calcitonin in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00525798. Accessed September 21, 2013."},{"key":"bibr31-1060028013509233","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research, Joint Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee Hearing, March 5, 2013. Calcitonin Salmon for the Treatment of Postmenopausal Osteoporosis. http:\/\/www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/reproductivehealthdrugsadvisorycommittee\/ucm343748.pdf"},{"key":"bibr32-1060028013509233","doi-asserted-by":"publisher","DOI":"10.1210\/endo.134.2.8299557"},{"key":"bibr33-1060028013509233","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0045(19970215)30:3<183::AID-PROS6>3.0.CO;2-N"},{"key":"bibr34-1060028013509233","first-page":"6060","volume":"61","author":"Segawa N","year":"2001","journal-title":"Cancer Res"},{"key":"bibr35-1060028013509233","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2011.11.004"},{"key":"bibr36-1060028013509233","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1852"},{"key":"bibr37-1060028013509233","unstructured":"European Medicines Agency. Questions and answers on the review of calcitonin-containing medicines. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Calcitonin_31\/WC500134838.pdf. Accessed September 22, 2013."},{"key":"bibr38-1060028013509233","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1852"},{"key":"bibr39-1060028013509233","doi-asserted-by":"publisher","DOI":"10.1016\/8756-3282(96)00084-1"},{"key":"bibr40-1060028013509233","unstructured":"Clarke T. FDA panel advises calcitonin salmon not be used for osteoporosis. Reuters. March 5, 2013. http:\/\/www.reuters.com\/article\/2013\/03\/05\/us-fda-calcitonin-idUSBRE92418H20130305. Accessed September 21, 2013."},{"key":"bibr41-1060028013509233","unstructured":"Health Canada. Synthetic calcitonin (salmon) nasal spray (NS): market withdrawal of all products, effective October 1st, 2013\u2014For Health Professionals. http:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/hc-sc\/2013\/34783a-eng.php. Accessed September 21, 2013."},{"key":"bibr42-1060028013509233","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5122(97)00071-6"},{"key":"bibr43-1060028013509233","doi-asserted-by":"publisher","DOI":"10.1007\/BF02556148"},{"key":"bibr44-1060028013509233","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650090110"},{"key":"bibr45-1060028013509233","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.050411"},{"key":"bibr46-1060028013509233","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(82)90815-4"},{"key":"bibr47-1060028013509233","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200006223422507"},{"key":"bibr48-1060028013509233","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199708213370806"},{"key":"bibr49-1060028013509233","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199708213370810"},{"key":"bibr50-1060028013509233","doi-asserted-by":"publisher","DOI":"10.1177\/003591576505800503"},{"key":"bibr51-1060028013509233","unstructured":"United States Department of Health and Human Services, Food and Drug Administration. Structured approach to benefit-risk assessment in drug regulatory decision-making. http:\/\/www.fda.gov\/downloads\/ForIndustry\/UserFees\/PrescriptionDrugUserFee\/UCM329758.pdf. Accessed September 21, 2013."},{"key":"bibr52-1060028013509233","unstructured":"Agency for Health Care Research and Quality. US preventive services task force procedures manual. http:\/\/www.uspreventiveservicestaskforce.org\/uspstf08\/methods\/procmanual.pdf. Accessed September 21, 2013. AHRQ Publication No. 08-05118-EF."},{"key":"bibr53-1060028013509233","doi-asserted-by":"publisher","DOI":"10.1210\/er.2001-9002"},{"issue":"1","key":"bibr54-1060028013509233","first-page":"CD001155","author":"Wells GA","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"bibr55-1060028013509233","first-page":"CD004523","author":"Wells G","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr56-1060028013509233","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809493"},{"key":"bibr57-1060028013509233","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C350"},{"key":"bibr58-1060028013509233","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.305.6853.556"},{"key":"bibr59-1060028013509233","doi-asserted-by":"publisher","DOI":"10.1007\/BF01623456"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028013509233","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028013509233","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028013509233","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:14:33Z","timestamp":1777374873000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028013509233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,25]]},"references-count":59,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["10.1177\/1060028013509233"],"URL":"https:\/\/doi.org\/10.1177\/1060028013509233","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,25]]}}}